In the News

09/21/2018 12:00 AM  | Real Clear Policy
08/28/2018 12:00 AM  | Fortune
07/19/2018 12:00 AM  | Investor's Business Daily
07/17/2018 12:00 AM  | Washington Examiner
06/04/2018 12:00 AM  | The Washington Times
05/31/2018 12:00 AM  | Investor's Business Daily
04/01/2018 12:00 AM  | Therapeutic Innovation & Regulatory Science Journal
03/26/2018 12:00 AM  | Medical Marketing & Media
03/09/2018 12:00 AM  | Investor's Business Daily
03/09/2018 12:00 AM  | Deseret News
Sign Up for Our Email Newsletter

RECENT NEWS

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

FDA  Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15
  • NEWSY
  • 01/04/2022 12:00 AM

FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15

CMPI's Peter Pitts discusses FDA approval of Pfizer COVID vaccine booster for children ages 12-15...  Read more

Should We Rethink The FDA Commissionership?

Should We Rethink The FDA Commissionership?

When one considers the FDA’s mission—to independently protect consumers and advance the public health—it is not at all cl...  Read more

DRUGWONKS BLOG